The Food and Drug Administration recently approved Philadelphia-based Lannett's neomycin sulfate tablets.
Neomycin sulfate [AC41]is an antibiotic that helps suppress normal bacterial flora of the bowel. The drug is meant to be taken in conjunction with erythromycin. Patients often take this drug pairing prior to having bowel surgeries to limit the amount of intestinal bacteria present.
Neomycin Sulfate also proves to be an affective adjunctive therapy for hepatic coma by reducing the ammonia-forming bacteria in the intestinal tract.
The drug will be available in 500 mg strength and is expected to launch in the next few months.
More articles on supply chain:
FDA strengthens warnings for two diabetes medications: 4 things to know
Batelle, Halyard to develop medical device wrap
FDA approves tool to detect hypoxia in brain